254 related articles for article (PubMed ID: 25855779)
1. Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.
Tomlinson JA; Caplin B; Boruc O; Bruce-Cobbold C; Cutillas P; Dormann D; Faull P; Grossman RC; Khadayate S; Mas VR; Nitsch DD; Wang Z; Norman JT; Wilcox CS; Wheeler DC; Leiper J
J Am Soc Nephrol; 2015 Dec; 26(12):3045-59. PubMed ID: 25855779
[TBL] [Abstract][Full Text] [Related]
2. Dimethylarginine Dimethylaminohydrolase 1 Deficiency Induces the Epithelial to Mesenchymal Transition in Renal Proximal Tubular Epithelial Cells and Exacerbates Kidney Damage in Aged and Diabetic Mice.
Shi L; Zhao C; Wang H; Lei T; Liu S; Cao J; Lu Z
Antioxid Redox Signal; 2017 Dec; 27(16):1347-1360. PubMed ID: 28594240
[TBL] [Abstract][Full Text] [Related]
3. Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.
Caplin B; Nitsch D; Gill H; Hoefield R; Blackwell S; MacKenzie D; Cooper JA; Middleton RJ; Talmud PJ; Veitch P; Norman J; Wheeler DC; Leiper JM
Kidney Int; 2010 Mar; 77(5):459-67. PubMed ID: 20010544
[TBL] [Abstract][Full Text] [Related]
4. Adenoviral-mediated overexpression of DDAH improves vascular tone regulation.
Torondel B; Nandi M; Kelly P; Wojciak-Stothard B; Fleming I; Leiper J
Vasc Med; 2010 Jun; 15(3):205-13. PubMed ID: 20219849
[TBL] [Abstract][Full Text] [Related]
5. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
Hu X; Atzler D; Xu X; Zhang P; Guo H; Lu Z; Fassett J; Schwedhelm E; Böger RH; Bache RJ; Chen Y
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1540-6. PubMed ID: 21493890
[TBL] [Abstract][Full Text] [Related]
6. Regulation of fluid reabsorption in rat or mouse proximal renal tubules by asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase 1.
Bell T; Araujo M; Luo Z; Tomlinson J; Leiper J; Welch WJ; Wilcox CS
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F74-F78. PubMed ID: 29513072
[TBL] [Abstract][Full Text] [Related]
7. Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass.
Jacobi J; Maas R; Arend M; Cordasic N; Hilgers KF
Int J Mol Sci; 2014 Mar; 15(4):5522-35. PubMed ID: 24690995
[TBL] [Abstract][Full Text] [Related]
8. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
9. ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
Rodionov RN; Heinrich A; Brilloff S; Jarzebska N; Martens-Lobenhoffer J; Bode-Böger SM; Todorov VT; Hugo CPM; Weiss N; Hohenstein B
Atheroscler Suppl; 2017 Nov; 30():319-325. PubMed ID: 29096857
[TBL] [Abstract][Full Text] [Related]
10. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
[TBL] [Abstract][Full Text] [Related]
11. Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
Xu X; Zhang P; Kwak D; Fassett J; Yue W; Atzler D; Hu X; Liu X; Wang H; Lu Z; Guo H; Schwedhelm E; Böger RH; Chen P; Chen Y
Basic Res Cardiol; 2017 Aug; 112(5):55. PubMed ID: 28819685
[TBL] [Abstract][Full Text] [Related]
12. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA.
Bulau P; Zakrzewicz D; Kitowska K; Leiper J; Gunther A; Grimminger F; Eickelberg O
Am J Physiol Lung Cell Mol Physiol; 2007 Jan; 292(1):L18-24. PubMed ID: 16891395
[TBL] [Abstract][Full Text] [Related]
13. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y
Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818
[TBL] [Abstract][Full Text] [Related]
14. Renal asymmetric dimethylarginine inhibits fibrosis.
Wu M; Yuan M; Wang Y; Tan B; Huang D; Wang C; Zou Y; Ye C
FEBS Open Bio; 2020 Oct; 10(10):2003-2009. PubMed ID: 32794631
[TBL] [Abstract][Full Text] [Related]
15. AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.
Amir M; Hassanein SI; Abdel Rahman MF; Gad MZ
Mol Biol Rep; 2018 Dec; 45(6):2411-2419. PubMed ID: 30284143
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of alanine-glyoxylate aminotransferase 2 protects from asymmetric dimethylarginine-induced endothelial dysfunction and aortic remodeling.
Rodionov RN; Jarzebska N; Burdin D; Todorov V; Martens-Lobenhoffer J; Hofmann A; Kolouschek A; Cordasic N; Jacobi J; Rubets E; Morawietz H; O'Sullivan JF; Markov AG; Bornstein SR; Hilgers K; Maas R; Pfluecke C; Chen Y; Bode-Böger SM; Hugo CPM; Hohenstein B; Weiss N
Sci Rep; 2022 Jun; 12(1):9381. PubMed ID: 35672381
[TBL] [Abstract][Full Text] [Related]
17. Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt.
Zhang P; Hu X; Xu X; Chen Y; Bache RJ
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):890-7. PubMed ID: 21212404
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.
Dayal S; Rodionov RN; Arning E; Bottiglieri T; Kimoto M; Murry DJ; Cooke JP; Faraci FM; Lentz SR
Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H816-25. PubMed ID: 18567702
[TBL] [Abstract][Full Text] [Related]
19. Correlations of DDAH1 transcript variants with human endothelial asymmetric dimethylarginine metabolizing activity.
Sun T; Zhou JP; Kuang DB; Li MP; Xiong Y; Tang J; Xia J; Bai YP; Yang GP; Li YJ; Chen XP
Am J Hypertens; 2013 Dec; 26(12):1437-44. PubMed ID: 23864585
[TBL] [Abstract][Full Text] [Related]
20. Novel Cellularly Active Inhibitor Regresses DDAH1 Induced Prostate Tumor Growth by Restraining Tumor Angiogenesis through Targeting DDAH1/ADMA/NOS Pathway.
Kami Reddy KR; Dasari C; Vandavasi S; Natani S; Supriya B; Jadav SS; Sai Ram N; Kumar JM; Ummanni R
ACS Comb Sci; 2019 Apr; 21(4):241-256. PubMed ID: 30673277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
